Related Experiment Video
Updated: May 5, 2026
07:13
Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
Published on: April 12, 2021
4.2K
Development and validation of the mobile adherence satisfaction scale (MASS) for medication adherence apps
Rajat Rana1, Baharudin Bin Ibrahim1, Hasniza Binti Zaman Huri1
1Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Universiti Malaya, 50603, Kuala Lumpur, Malaysia.
Research in Social & Administrative Pharmacy : RSAP
|August 1, 2024
Summary
The Mobile Adherence Satisfaction Scale (MASS) was developed to measure user satisfaction with mHealth apps for medication adherence. Positive user interface and features are crucial for sustained engagement and adherence.
Area of Science:
- Health Informatics
- Patient Adherence Research
- Mobile Health (mHealth) Technology Evaluation
Background:
- Medication non-adherence is a significant challenge in managing chronic diseases.
- Mobile health (mHealth) applications offer a promising avenue to improve medication adherence.
- Existing tools for assessing user satisfaction with mHealth adherence apps are limited.
Purpose of the Study:
- To develop and validate the Mobile Adherence Satisfaction Scale (MASS).
- To assess user satisfaction with mHealth applications designed to enhance medication adherence.
- To identify key factors influencing user satisfaction in mHealth adherence tools.
Main Methods:
- A mixed-methods approach involving literature review, expert consultation, and patient interviews.
- Development of the MASS using a two-round Delphi technique, followed by pilot testing.
- Validation of the 26-item, six-dimension MASS with 135 adult patients using exploratory and confirmatory factor analyses.
Main Results:
- The MASS demonstrated high reliability and validity, with Cronbach's alpha > 0.70 for all dimensions.
- Exploratory and confirmatory factor analyses supported a six-dimension structure for the MASS.
- User interface and feature satisfaction significantly positively impacted general satisfaction, explaining 23.1% of the variance.
Conclusions:
- The MASS is a reliable and valid instrument for evaluating user satisfaction with mHealth adherence applications.
- Optimizing the user interface and features of mHealth apps is essential for promoting long-term user engagement.
- Improved user satisfaction through thoughtful design can contribute to better medication adherence outcomes.
Related Concept Videos
01:10In Vitro Drug Release Testing: Overview, Development and Validation
593
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
593
01:14Drug Dissolution: Requirements and Profile Comparison
500
The acceptance criteria for dissolution profile data are anchored in Q values, representing the percentage of drug dissolved within a specified period. This assessment unfolds in three stages:First Stage: The test passes if all six drug dosage units are equal to or greater than Q plus 5%; otherwise, the sample proceeds to the second stage.Second Stage: The average of twelve units must be equal to or greater than Q, with no unit falling below Q - 15% to pass; if not, it progresses to the final...
500
01:20Drug Product Performance: In Vitro–In Vivo Correlation
431
In pharmaceutical development, it's crucial to establish a predictive in vitro–in vivo correlation (IVIVC) for two or more formulations to gain a comprehensive understanding of release properties. IVIVC reduces the need for costly in vivo studies and facilitates the establishment of meaningful dissolution specifications with significant cost savings and decreased regulatory burden. Furthermore, a meaningful IVIVC should predict Cmax and AUC within 20%, aligning with FDA guidance while...
431
01:29Clinically Relevant Drug Product Specifications: Methods of Establishment
300
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
300
01:16Therapeutic Drug Monitoring: Overview and Classification
642
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
642
01:26Therapeutic Drug Monitoring: Drug Analysis Methods
342
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
342